ClearPoint Neuro, Inc. (NASDAQ:CLPT) Shares Bought by Taylor Frigon Capital Management LLC

Taylor Frigon Capital Management LLC increased its holdings in ClearPoint Neuro, Inc. (NASDAQ:CLPTGet Rating) by 2.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 178,780 shares of the company’s stock after acquiring an additional 4,054 shares during the quarter. Taylor Frigon Capital Management LLC owned approximately 0.73% of ClearPoint Neuro worth $1,852,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of CLPT. Advisor Group Holdings Inc. boosted its position in shares of ClearPoint Neuro by 131.5% during the 1st quarter. Advisor Group Holdings Inc. now owns 2,153 shares of the company’s stock worth $66,000 after purchasing an additional 1,223 shares in the last quarter. Nisa Investment Advisors LLC acquired a new position in shares of ClearPoint Neuro during the 2nd quarter valued at about $27,000. State Street Corp increased its position in ClearPoint Neuro by 0.7% during the 1st quarter. State Street Corp now owns 303,335 shares of the company’s stock worth $3,158,000 after purchasing an additional 2,125 shares in the last quarter. Castle Wealth Management LLC acquired a new stake in ClearPoint Neuro during the 2nd quarter worth approximately $33,000. Finally, Charles Schwab Investment Management Inc. increased its position in ClearPoint Neuro by 5.3% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 49,887 shares of the company’s stock worth $520,000 after purchasing an additional 2,532 shares in the last quarter. 15.11% of the stock is owned by institutional investors and hedge funds.

ClearPoint Neuro Stock Down 3.1 %

NASDAQ CLPT traded down $0.28 on Wednesday, reaching $8.81. The company had a trading volume of 5,297 shares, compared to its average volume of 67,094. The firm has a market capitalization of $216.33 million, a PE ratio of -13.17 and a beta of 1.09. The company has a debt-to-equity ratio of 0.25, a current ratio of 8.83 and a quick ratio of 7.47. The firm has a 50-day moving average of $9.04 and a 200-day moving average of $10.99. ClearPoint Neuro, Inc. has a 1 year low of $7.00 and a 1 year high of $16.96.

ClearPoint Neuro (NASDAQ:CLPTGet Rating) last released its earnings results on Tuesday, November 8th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.04. ClearPoint Neuro had a negative return on equity of 36.56% and a negative net margin of 82.40%. The company had revenue of $5.15 million during the quarter, compared to analysts’ expectations of $5.51 million.

ClearPoint Neuro Company Profile

(Get Rating)

Clearpoint Neuro, Inc engages in the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain and heart. The firm conducts its procedures under direct, intra-procedural magnetic resonance imaging guidance. Its product platform consists of the ClearPoint system and ClearTrace system.

Featured Stories

Want to see what other hedge funds are holding CLPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ClearPoint Neuro, Inc. (NASDAQ:CLPTGet Rating).

Institutional Ownership by Quarter for ClearPoint Neuro (NASDAQ:CLPT)

Receive News & Ratings for ClearPoint Neuro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ClearPoint Neuro and related companies with MarketBeat.com's FREE daily email newsletter.